Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-955176 DDI with Probe Substrates in Healthy Subjects
NCT02578277Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-955176 in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Nov 2015; status: completed.
02
Drugs
BMS-955176
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02578277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578277.